Key result
TAVR utilization increases markedly while patient comorbidities decline, including ~38% less baseline heart failure.
Why the study?
Trends in the utilization of TAVR and changes in the characteristics of patients undergoing first-time TAVR needed investigation.
How have the utilization rates and patient characteristics for TAVR changed over time between 2008 and 2020?
Cohort (n=6,097)
Yes
How have the utilization rates and patient characteristics for TAVR changed over time between 2008 and 2020?
TAVR utilization has expanded significantly over time to include patients with fewer comorbidities, though it remains predominantly utilized in older populations.
No takes yet. Share an insight, caveat, or question.
TAVR expansion to lower-comorbidity patients warrants outcome surveillance; leaves open whether benefits extend beyond current selection criteria.
Strange et al. (2021) conducted a cohort in Aortic valve disease requiring TAVR (n=6,097). Transcatheter aortic valve replacement (TAVR) vs. Calendar year cohorts (2008-2010 vs 2017-2020) was evaluated on Trends in utilization and patient characteristics. TAVR utilization increased markedly from 2008 to 2020, with patients exhibiting fewer comorbidities over time (e.g., heart failure decreased from 40.5% to 25.2%) while age remained stable.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: